F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
It’s impossible to imagine how many lives antibiotics have saved since penicillin was first synthesized by Alexander Fleming in 1928 - certainly tens, if not hundreds of millions. 14 December 2017
Clinical-stage US biotech Provectus Biopharmaceuticals has reached a settlement with the US Securities and Exchange Commission (SEC) in connection with investigations relating to two former executives and the company. 13 December 2017
Mundipharma network of independent associated companies has appointed Alberto Martinez as president and chief executive of Mundipharma International, with immediate effect. 13 December 2017
Swiss pharmaceutical giant Roche, which invested 1.5 billion roubles ($25 million) in the localization of the production of its anti-cancer drug Gaziva/Gazyvaro (obinutuzumab) in Russia in order to participate in public procurements, may not implement its plans, reports The Pharma Letter’s local correspondent. 12 December 2017
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago. 11 December 2017
The occasion of World AIDS Day was as good as any for India to launch a National Strategic Plan 2017-24, aimed at eradicating HIV/ AIDS by 2030. The country has over 2.1 million people living with HIV, the third largest number of people with HIV in the world, reports The Pharma Letter’s India correspondent. 8 December 2017
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial resistance (AMR). AMR, widely accepted as one of the major global challenges of the 21st century, is currently implicated in around 700,000 deaths worldwide, including 50,000 in the USA and Europe alone. 7 December 2017
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was set up just a couple of years ago. 5 December 2017
The global life sciences and pharmaceuticals sector is undergoing a wave of strategic M&A activity, as incumbents make acquisitions to enhance the technological capabilities they need to keep pace with the evolution of the industry. 4 December 2017
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Germany’s Bayer announced today it will further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership. 1 December 2017
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
The Russian government has surprisingly decided to make concessions to domestic and global drugmakers operating in the country through the extension of the time, required for the mandatory labeling of drugs, reports The Pharma Letter’s local correspondent. 30 November 2017
Russian biotech and biosimilars company Biocad is launching production in North Africa. As part of these plans, the company will start manufacturing of anti-cancer drugs at the facilities of the Moroccan pharmaceutical company SothemaLabs, reports The Pharma Letter’s local correspondent. 29 November 2017
Denmark-based allergy specialist ALK-Abelló today announced that Helle Skov, executive vice president of product supply and a member of ALK's board of management, leaves the company by mutual agreement. 29 November 2017
Charlie Johnson, chief executive of antibody drug conjugate (ADC) specialist ADC Bio, considers some of the challenges and solutions involved with developing ADC therapeutics in an Expert View piece. 29 November 2017
Mads Krogsgaard Thomsen, Novo Nordisk employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one." 28 November 2017
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news